Lung cancer remains one of the most widespread and deadliest malignant tumors globally, with a particularly high mortality rate among all cancers. Recently, immunotherapy, particularly immune ...
During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed ...
Researchers developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma - a ...
AbTree Biologics AG has signed an exclusive co-development and commercialization partnership with Shilpa Biologicals Pvt Ltd. (a fully owned subsidiary of Shilpa Medicare Limited) for its novel ...
The novel therapy is anticipated to function like PD-1/PD-L1 blockade with significant clinical efficacy results in ...
Karnataka: Shilpa Biologicals Pvt Ltd., a fully owned subsidiary of Shilpa Medicare Limited has signed an exclusive ...
Shilpa Medicare soared 10.46% to Rs 696.15 after the company's wholly owned subsidiary, Shilpa Biologicals, inked a strategic partnership with Switzerland-based mAbTree Biologics AG to co-develop and ...
6d
The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...
The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...
While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...
SPP1+ Macrophages Identified as Key Drivers and Therapeutic Targets In Colorectal Cancer Progression
Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related deaths worldwide.
Researchers from the VIB-KU Leuven Center for Cancer Biology, in collaboration with other scientists, have discovered a way ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback